Lineage Cell Therapeutics, Inc. LCTX

1.03 0.08 8.42% as of 25 Sep
Market cap
$239.7M
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
10.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S ratio
52.25 66.21 23.15 36.85 144.62 92.84 14.20 21.04 10.54 26.40
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 323.29 0.00 0.00 0.00
P/Operating CF
(34.96) (40.34) (19.87) (23.45) (46.81) (68.62) (25.15) (31.27) (15.77) (78.78)
P/B ratio
2.37 1.39 1.25 1.16 2.78 4.43 2.90 3.03 1.30 8.87
Price to Tangible BV
2.57 1.45 1.30 2.48 7.06 12.07 14.33 39.30 5.06 394.55
EV/Sales
48.66 55.21 17.01 28.13 121.87 79.41 10.27 17.08 5.51 22.57
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
(6.81) (6.26) (2.75) (3.10) (11.27) (14.63) 142.64 (5.35) (2.27) (17.37)
EV/FCF
(6.43) (6.03) (2.63) (3.06) (11.24) (14.42) 233.83 (5.23) (2.21) (16.90)
Quick Ratio
2.70 5.99 5.06 8.42 5.35 2.32 3.06 2.02 3.47 4.99
Current Ratio
2.90 6.20 5.34 8.86 5.66 2.37 3.16 2.14 3.65 5.20
Net Debt/EBITDA
0.40 1.09 0.80 0.86 1.69 1.21 2.65 1.48 2.28 2.64
Debt/Assets
1.03% 0.09% 0.10% 0.06% 0.02% 0.02% 0.07% 0.09% 0.06% 0.03%
Debt/Equity
0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
0.05 0.02 0.04 0.03 0.02 0.03 0.10 0.08 0.09 0.13
Operating CF/Net income
(1.26) 1.53 0.67 2.73 0.96 0.55 (0.04) 1.33 1.24 0.30
Capex/Depreciation
(0.49) (0.29) (0.43) (0.11) (0.02) (0.38) (0.60) (0.86) (1.00) (0.03)
Interest Coverage
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
32.44% (13.55%) (35.86%) (11.51%) (20.01%) (46.25%) (32.27%) (32.08%) (26.77%) (105.57%)
ROA
28.30% (12.65%) (33.46%) (10.31%) (17.69%) (30.46%) (17.62%) (19.13%) (17.37%) (56.27%)
ROIC
(33.73%) (19.26%) (42.40%) (30.14%) (30.84%) (94.43%) (99.51%) (58.07%) (45.86%) 0.00%
Return on Tangible Assets
150.36% (48.39%) (129.99%) (19.78%) (49.33%) (62.07%) (56.27%) (94.54%) (47.39%) (126.17%)
Average Days of Receivables
71.30 321.51 272.14 2,485.95 0.80 4,274.73 7.37 30.40 24.52 22.34
Research and Development Expense of Revenue
609.59% 694.74% 420.11% 510.61% 674.53% 781.25% 95.13% 175.57% 131.30% 121.80%
Selling, General and Administrative Expense of Revenue
479.93% 576.11% 495.71% 683.67% 852.74% 419.53% 153.08% 193.43% 191.29% 126.82%
Intangible Assets out of Total Assets
0.07 0.04 0.03 0.47 0.53 0.33 0.46 0.57 0.51 0.38
Share Based Compensation of Revenue
134.24% 113.71% 108.30% 101.85% 128.48% 85.72% 29.16% 51.87% 53.45% 32.65%
Graham Net Nets
0.04 0.15 0.23 0.33 0.12 0.07 0.04 0.00 0.15 (0.03)
Graham Number
3.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
9.88% (5.50%) (38.46%) (4.49%) (7.74%) (10.61%) (12.20%) (11.93%) (20.00%) (16.77%)
Free Cash Flow Yield
(14.49%) (13.82%) (27.97%) (24.94%) (7.50%) (5.93%) 0.31% (15.54%) (23.63%) (5.06%)
Revenue per Share
0.06 0.03 0.04 0.02 0.01 0.03 0.09 0.05 0.05 0.06
Operating CF per Share
(0.43) (0.27) (0.24) (0.22) (0.13) (0.14) 0.01 (0.17) (0.12) (0.08)
Capex per Share
(0.03) (0.01) (0.01) 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.46) (0.28) (0.25) (0.22) (0.13) (0.15) 0.00 (0.17) (0.12) (0.08)
Cash per Share
0.23 0.33 0.24 0.21 0.28 0.35 0.34 0.21 0.24 0.24
Shareholders Equity per Share
1.34 1.43 0.73 0.76 0.63 0.55 0.42 0.36 0.38 0.19
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
1.34 1.43 0.73 0.76 0.63 0.55 0.42 0.36 0.38 0.19
Free Cash Flow
(44.85) (31.64) (32.30) (32.30) (19.79) (23.90) 0.65 (29.24) (23.66) (19.44)
Working Capital
16.80 35.74 29.55 51.03 36.23 64.43 41.02 20.48 37.02 47.79
Capital Expenditures
(2.53) (1.13) (1.41) (0.36) (0.04) (0.34) (0.41) (0.67) (0.56) (0.52)
Net Current Asset Value
13.59 33.65 26.94 43.29 31.18 27.90 8.27 (0.55) 14.79 (10.08)
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.43 0.33 0.28 0.10 0.02 0.08 0.03 0.08 0.06 0.04
Net Profit Margin
566.81% (577.67%) (922.01%) (333.12%) (1,130.83%) (990.99%) (178.69%) (240.20%) (195.90%) (436.47%)
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.94 0.71 0.56 0.38 0.34 0.18 0.12 0.35 0.25 6.03
Cash ROIC
(30.94%) (17.79%) (29.83%) (28.25%) (18.57%) (19.05%) (3.55%) (31.57%) (20.29%) (21.67%)
Accounts Receivable Turnover
4.23 1.65 1.47 0.25 0.15 0.17 0.58 17.17 13.74 19.04
Accounts Payable Turnover
0.04 0.03 0.05 0.07 0.06 0.08 0.04 0.09 0.06 0.02
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Average Days of Payables
7,283.69 12,423.04 7,811.24 4,629.83 6,459.08 7,158.97 4,315.82 3,410.66 5,941.63 17,952.50
Days of Inventory on Hand
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Average Receivables
1.40 2.10 3.38 13.83 11.97 25.42 25.57 0.52 0.69 0.76
Average Payables
8.26 6.43 6.09 5.84 6.02 17.39 18.29 7.44 5.85 6.31
Average Assets
118.62 157.91 137.45 113.57 116.71 141.25 149.10 112.34 107.12 112.90
Average Common Equity
103.48 147.39 128.25 101.75 103.19 93.01 81.42 66.98 69.52 60.18

Fold the line items

Columns are period end dates